immatics biotechnologies

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.

The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.

immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

immatics biotechnologies headquartered in Europe, operates in the Biotechnology, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $119.5B in funding across 156 round(s). With a team of 101-250 employees, immatics biotechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - immatics biotechnologies, raised $52.1M. Discover more about their projects, partnerships, and impact on our platform.